Studies on the structure-activity relationship of endostatin: Synthesis of human endostatin peptides exhibiting potent antiangiogenic activities

Journal of Medicinal Chemistry

Volumn 46, Issue 19, 2003, Pages 4165-4172

  Chillemi, Francesco ^a   Francescato, Pierangelo ^a   Ragg, Enzio ^a   Cattaneo, Maria Grazia ^b   Pola, Sandra ^b   Vicentini, Lucia ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; MATRIGEL; PEPTIDE;

ALPHA HELIX; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL PROLIFERATION; CRYSTAL STRUCTURE; DISULFIDE BOND; DRUG POTENCY; ENDOTHELIUM CELL; PEPTIDE SYNTHESIS; PROTEIN TERTIARY STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; RETINOPATHY; RHEUMATOID ARTHRITIS; SOLID PHASE EXTRACTION; STRUCTURE ACTIVITY RELATION; VASCULARIZATION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; CIRCULAR DICHROISM; COLLAGEN; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0141455068     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0308287     Document Type: Article

References (23)

1. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasions, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277-285.
2. Kisker, O.; Becker, C. M.; Prox, D.; Fannon, M.; D'Amato, R.; Flynn, E.; Fogler, W. E.; Lee Sim, B. K.; Allred, E. N.; Pirie-Shepherd, S. R.; Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001, 61, 7669-7674.
3. Cao, Y.; Ji, R. W.; Davidson, D.; Schaller, J.; Marti, D.; Sohndel, S.; McCance, S. G.; O'Reilly, M. S.; Llinàs M.; Folkman, J. Kringle domains of Angiostatin. J. Biol. Chem. 1996, 271, 29461-29467.
4. Oh, S. P.; Warman, M. L.; Seldin, M. F.; Cheng, S. D.; Knoll, J. H. M.; Timmons, S.; Olsen B. R. Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the α1(XVIII) collagen gene to mouse chromosome 10 and human chromosome 21. Genomics 1994, 19, 494-499.
5. Perletti, G.; Concari, P.; Giardini, R.; Marras, E.; Piccinini, F.; Folkman, J.; Chen, L. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumor. Cancer Res. 2000, 60, 1793-1796.
6. Dong, S.; Cole, G. J.; Halfter, W. Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites. J. Biol. Chem, 2003, 278, 1700-2003.
7. Hohenester, E.; Sasaki, T.; Olsen, B. R.; Timpl, R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution. EMBO J. 1998, 17, 1656-1664.
8. Ding, Y. H.; Javaherian, K.; Lo, K. M.; Chopra, R.; Boehm, T.; Lanciotti, J.; Harris, B. A.; Li, Y.; Shapiro, R.; Hohenester, E.; Timpl, R.; Folkman, J. ; Wiley: D. C. Zinc-dependent dimers observed in crystals of human endostatin. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10443-10448.
9. Yamaguchi, N.; Anand-Apte, B.; Lee, M.; Sasaki, T.; Fukai, N.; Shapiro, R.; Que, I.; Lowik, C.; Timpl, R.; Olsen, B. R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999, 18, 4414-4423.
10. Luo, P.; Baldwin, R. L. Mechanism of helix induction by trifluoroethanol: a framework for extrapolating the helix-forming properties of peptides from trifluoroethanol/water mixtures back to water. Biochemistry 1997, 36, 8413-8421.
11. Wüthrich, K. NMR of Proteins and Nucleic Acids; John Wiley & Sons: New York, 1986; pp 162-166.
12. Cattaneo, M. G.; Pola, S.; Francescato, P.; Chillemi, F.; Vicentini, L. M. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell Res. 2003, 283, 230-236.
13. Kranenburg, O.; Kroon-Batenburg, M. G.; Reijerkerk, A.; Wu. Y.; Voest, E. E.; Gebbink, M. F. B. G. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett. 2003, 539, 149-155.
14. Rubin, B.; Engel, S. L.; Drungis, A. M.; Dzelzkalns, M.; Grigas, E. O.; Waugh, M. H.; Yiacas, E. Cholecystokinin-like activities in guinea pigs and in dogs of C-terminal octapeptide (SQ 19.844) of cholecystokinin. J. Pharm. Sci. 1969, 58, 955-959.
15. Morbidelli, L.; Donnini, S.; Chillemi, F.; Giachetti, A.; Ziche, M. Angiosuppressive and angiostimulatory effects exerted by synthetic parzial sequences of endostatin. Clin. Cancer Res. 2003 (in press).
16. Herbst, R. S.; Hess, K. R.; Tran, H. T.; Tseng, J. E.; Mullani, N. A.; Charnsangavej, C.; Madden, T.; Davis, D. W.; McConkey, D. J.; O'Reilly, M. S.; Ellis, L. M.; Pl, R.; Pluda, J.; Hong, W. K.; Abbruzzese, J. L. Phase I study of recombinant human endostatin in patient with advanced solid tumors. J. Clin. Oncol. 2002, 20, 3792-3803.
17. Eder, J. P.; Supko, J. G.; Clark, J. W.; Puchalski, T. A.; Garcia-Carbonero, R.; Ryan, D. P.; Shulman, L. N.; Proper, J.; Kirvan, M.; Rattner, B.; Connors, S.; Keogan, M. T.; Janicek, M. J.; Fogler, W. E.; Schnipper, L.; Kinchla, N.; Sidor, C.; Phillips, E.; Folkman, J.; Kufe, D. W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 2002, 20, 3772-3784.
18. Pradilla, G.; Legnani F. G.; Tyler, D. M.; Chillemi, F.; Francescato, P. ; Brem, H.; Olivi, A.; DiMeco, F. Enhanced antitumour efficacy by combining carmustin with endostatin peptide 6-49 in an intracranial glioma model. Manuscript in preparation.
19. Chillemi, F.; Vicentini, L.; Francescato, P. PCT Patent. International Publication Number: WO 02/068457 A2. Applicant: University of Milan. Antiangiogenic peptides. Priority Data: 27.02.2001 (esp@cenet).
20. Chillemi, F.; Francescato, P.; Ziche, M. PCT Patent. International Publication Number: WO 00/63249. Applicants: University of Milan and University of Florence. Polypeptides derived from endostatin exhibiting antiangiogenic activity. Priority Data: 15.04.1999 (esp@cenet).
21. Jaffe, E. A.; Nachman, R. L.; Becker, C. G.; Minck, C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 1973, 52, 2745-2756.
22. Passaniti, A.; Taylor, R. M.; Pili, R.; Guo, Y.; Long, P. V.; Haney, J. A.; Pauly, R. R.; Grant, D. S.; Martin, G. R. A Simple, quantitative method for assessing angiogenic and antiangiogenic agents using reconstituted membrane, heparin and fibroblast growth factor. J. Neurosurg. 1992, 77, 519-528.
23. Albini, A.; Fontanini, G.; Masiello, L.; Tacchetti, C.; Bigini, D.; Luzzi, P.; Noomam, D. M.; Sterler-Stevenson, W. Angiogenic potential in vivo by Kaposi sarcoma cell-free supernatants and HIV1-tat product: inhibition of KS-like lesions by TIMP-2. AIDS (London) 1994, 8, 1237-1244.